These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32561994)

  • 1. Rasburicase improves the outcome of acute kidney injury from typical hemolytic uremic syndrome.
    Cho MH; Ahn YH; Lim SH; Kim JH; Ha IS; Cheong HI; Kang HG
    Pediatr Nephrol; 2020 Nov; 35(11):2183-2189. PubMed ID: 32561994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rasburicase for hyperuricemia in hemolytic uremic syndrome.
    Acosta AA; Hogg RJ
    Pediatr Nephrol; 2012 Feb; 27(2):325-9. PubMed ID: 22089328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperuricemia: an unrecognized risk factor for kidney-related sequelae in children with hemolytic uremic syndrome.
    Balestracci A; Meni Battaglia L; Toledo I; Beaudoin L; Martin SM; Grisolía NA; Hogg RJ
    Pediatr Nephrol; 2023 May; 38(5):1547-1557. PubMed ID: 36227433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome of diarrhea-associated hemolytic uremic syndrome is poorly related to markers of kidney injury at 1-year follow-up in a population-based cohort.
    Monet-Didailler C; Godron-Dubrasquet A; Madden I; Delmas Y; Llanas B; Harambat J
    Pediatr Nephrol; 2019 Apr; 34(4):657-662. PubMed ID: 30368614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [RASBURICASE TREATMENT FOR NEONATAL ACUTE KIDNEY INJURY - A CASE REPORT].
    Shasha-Lavsky H; Awadia P; Sheffer V; Weissman I
    Harefuah; 2021 Dec; 160(12):806-809. PubMed ID: 34957716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999-2008.
    Jenssen GR; Vold L; Hovland E; Bangstad HJ; Nygård K; Bjerre A
    BMC Infect Dis; 2016 Jun; 16():285. PubMed ID: 27297224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rasburicase in hemolytic uremic syndrome related to Shiga toxin-producing Escherichia coli: a report of nine cases.
    Balestracci A; Meni Battaglia L; Martin SM; Toledo I
    Pediatr Nephrol; 2020 Jun; 35(6):1133-1137. PubMed ID: 32152725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it the right time to subject children with acute kidney injury to rasburicase trials?
    Jarmoliński T; Zaniew M; Tousty J; Runowski D
    Pediatr Nephrol; 2012 Jul; 27(7):1201-2. PubMed ID: 22410796
    [No Abstract]   [Full Text] [Related]  

  • 9. Rasburicase improves hyperuricemia in infants with acute kidney injury.
    Hobbs DJ; Steinke JM; Chung JY; Barletta GM; Bunchman TE
    Pediatr Nephrol; 2010 Feb; 25(2):305-9. PubMed ID: 19936796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification.
    Khalighi PR; Martens KL; White AA; Li S; Silgard E; Frieze D; Garcia DA; Li A
    J Oncol Pharm Pract; 2020 Apr; 26(3):529-535. PubMed ID: 31167612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single dose of rasburicase for treatment of hyperuricemia in acute kidney injury: a report of 3 cases.
    Hooman N; Otukesh H
    Iran J Kidney Dis; 2011 Mar; 5(2):130-2. PubMed ID: 21368393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rasburicase versus intravenous allopurinol for non-malignancy-associated acute hyperuricemia in paediatric cardiology patients.
    Moss JD; Wu M; Axelrod DM; Kwiatkowski DM
    Cardiol Young; 2019 Sep; 29(9):1160-1164. PubMed ID: 31451121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
    Shaikh SA; Marini BL; Hough SM; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Apr; 24(3):176-184. PubMed ID: 28077046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial dysfunction during long-term follow-up in children with STEC hemolytic-uremic syndrome.
    Kreuzer M; Sollmann L; Ruben S; Leifheit-Nestler M; Fischer DC; Pape L; Haffner D
    Pediatr Nephrol; 2017 Jun; 32(6):1005-1011. PubMed ID: 28180952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
    Martens KL; Khalighi PR; Li S; White AA; Silgard E; Frieze D; Estey E; Garcia DA; Hingorani S; Li A
    Leuk Res; 2020 Feb; 89():106298. PubMed ID: 31945598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertension and mild chronic kidney disease persist following severe haemolytic uraemic syndrome caused by Shiga toxin-producing Escherichia coli O104:H4 in adults.
    Derad I; Obermann B; Katalinic A; Eisemann N; Knobloch JK; Sayk F; Wellhöner P; Lehnert H; Solbach W; Süfke S; Steinhoff J; Nitschke M
    Nephrol Dial Transplant; 2016 Jan; 31(1):95-103. PubMed ID: 26180049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-FABP and IL-6 as markers of chronic kidney damage in children after hemolytic uremic syndrome.
    Lipiec K; Adamczyk P; Świętochowska E; Ziora K; Szczepańska M
    Adv Clin Exp Med; 2018 Jul; 27(7):955-962. PubMed ID: 29905409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rasburicase improves hyperuricemia in patients with acute kidney injury secondary to rhabdomyolysis caused by ecstasy intoxication and exertional heat stroke.
    Lin PY; Lin CC; Liu HC; Lee MD; Lee HC; Ho CS; Chiu NC; Peng CC; Huang FY; Tsai JD
    Pediatr Crit Care Med; 2011 Nov; 12(6):e424-7. PubMed ID: 21572370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
    Herrington JD; Dinh BC
    J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression.
    Garg AX; Suri RS; Barrowman N; Rehman F; Matsell D; Rosas-Arellano MP; Salvadori M; Haynes RB; Clark WF
    JAMA; 2003 Sep; 290(10):1360-70. PubMed ID: 12966129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.